NEWS

General Information

The aim of the ERDERA Partnership is to improve the health and well-being of the 30 million people diagnosed with rare diseases by making Europe a world leader in rare disease research and innovation, and to provide essential healthcare services to these patients through better prevention, diagnosis and treatment. In addition, ERDERA aims to create a multi-stakeholder rare disease ecosystem that has the potential to pioneer digital transformation change in rare disease research and innovation, based on health research data, by developing new diagnostic and therapeutic pathways.

The Partnership has outlined several components of activities, including:

  • Joint Transnational calls for interdisciplinary and collaborative research and innovation projects;

  • Setting up of the Clinical research network to accelerate the clinical trials preparedness on rare diseases;

  • Alignment and integration of national and European research plans;

  • Knowledge and data sharing and analyses services;

  • Enhancing international cooperation by supporting the Scientific Secretariat of the International Rare Disease Research Consortium (IRDiRC);

  • Boost public-private research collaboration models;

  • Capacity-building and training, for researchers, but also clinicians and patients. 

Budget

With over 170 partners from 37 countries, a 7-year duration and a total estimated budget of €380 million, ERDERA is the largest co-funded partnership in the field of rare disease research and innovation.

Call Information

Grant Agreement was signed on 20 August 2024. The first Joint Transnational Call of the Partnership is expected to be opened for applications on 10 December 2024.

Project proposals to be submitted within the scope of the ERDERA 2025 Call are expected to include at least two of the research field titles listed below.

  • Development of novel therapies in a pre-clinical setting

  • Creation and validation of predictive and pharmacodynamic biomarkers

  • Replication of pre-clinical findings to enhance reliability

  • Pre-clinical proof-of-concept studies for therapy readiness

     

Call Schedule: 

  • Deadline for submission of pre-proposals to the Joint Call Secretariat: 13/02/2025 (14:00, CET)

  • Deadline for the TÜBİTAK national application of pre- proposals: 21/02/2025 (23:59, UTC+3)

  • Deadline for the e-signature processes of the TÜBİTAK national application of pre-proposals: 26/02/2025 (23:59, UTC+3)

  • Deadline for submission of full proposals to the Joint Call Secretariat: 09/07/2025 (14:00, CET)

     

You can find detailed information about the International Call announcement and application process from the link below.

It is strongly recommended that you review the ERDERA 2025 National Application Rules document (in Turkish) to learn about national processes. 

For information on the International Application and the ERDERA 2025 Call:

M. Merve POLAT, PhD

Directorate for EU Framework Programmes 

e-mail: erdera@tubitak.gov.tr 

Phone: 0312 298 17 82

For Information on the National Application for TÜBİTAK 1071 Program

Arif DUYAR

International Cooperation Projects Research Support Group (UPAG)

e-mail: arif.duyar@tubitak.gov.tr 

Phone: 0312 298 16 28

Other Informations

You may also contact the Joint Call Secretariat for questions regarding international processes: SelteneErkrankungen@dlr.de

You can find more information about the Partnership here and follow current developments on the ERDERA website.

 

Related Cluster

Cluster 1: Health